The trial is intended to investigate the basic pharmacokinetics, excretion pathways and metabolism of BI 690517 and its metabolites.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
14
BI 690517 (C-14)
BI 690517
ICON
Groningen, Netherlands
Part A: Fraction of [14C] radioactivity excreted into urine given as percentage of the administered dose in the time interval from 0 to last quantifiable time point (fe urine,0-tz )
Time frame: Up to 22 days.
Part A: Fraction of [14C] radioactivity excreted into feces given as percentage of the administered dose in the time interval from 0 to last quantifiable time point (fe feces, 0-tz)
Time frame: Up to 22 days.
Part B: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after intravenous administration (AUC0-∞)
Time frame: Up to 3 days.
Part B: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after oral administration (AUC0-∞)
Time frame: Up to 3 days.
Part A: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz)
Time frame: Up to 8 days.
Part A: Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to 8 days.
Part B: Maximum measured concentration of the analyte in plasma (Cmax)
Time frame: Up to 3 days.
Part B: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable time point (AUC0-tz)
Time frame: Up to 3 days.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.